RESPONDENT INFORMATION SHEET AND PARENT INFORMED CONSENT FORM

1. Title of study: A Phase II open label, single arm, single centre clinical study on the effect of a moisturiser containing tocotrienol rich composition on mild to moderate atopic dermatitis in children

2. Name of investigator and institution: Dr. How Kang Nien, Universiti Putra Malaysia

3. Name of sponsor: Lipidware Sdn. Bhd.

4. Introduction:

- You are invited to participate in this research study because your child/ children have mild to moderate atopic dermatitis (AD) and you wish to use a more natural, steroid-free topical moisturizer on daily-basis as an aid to improve your child's condition.
- The details of the research trial are described in this document. It is important that you understand why the research is being done and what it will be involving prior to your enrollment into the study.
- Please take your time to read through and consider this information carefully before you decide if you are willing to participate. Please ask the study staffs if anything is unclear or if you would like more information.
- To participate in this study, you may be required to provide the medical officer in charge with medical information including health history, medical check-ups and potential allergies; you may harm yourself if you are not truthful with the information provided.
- Please sign this informed consent form only after you are properly informed and well understood regarding this study.
- Your participation in this study is voluntary. If you decide not to take part in this study it will not affect the care you receive and will not result in any loss of benefits to which you are otherwise entitled.
- You may withdraw from the study at any time. If you withdraw, any data collected from you up to your withdrawal will still be used for the study. Your refusal to participate or withdrawal will not affect any medical or health benefits to which you are otherwise entitled.

- This study has been approved by the Ethical Committee for Research Involving Human Subjects (JKEUPM), Universiti Putra Malaysia.

5. What is the purpose of the study?

The purpose of this study is to assess the effectiveness and safety of a moisturizer containing tocotrienol rich fraction on mild-to-moderate atopic dermatitis in children between 1 month to 12 years for the treatment of AD. This research is necessary because eczema poses significant impact and inconveniences to the quality of life and health-care resources of both parents and children, mainly because of sleep deprivation and demoted self-esteemed (due to itchiness, scarring, lichenification, peer pressure and time to care), that would in turn affects the child's growth and development. The study aimed to provide an effective daily-use emollient that is more natural and steroid-free alternative for children.

A total of 33 subjects like yourself from various parts of Malaysia will be participating in this study. The whole study will last about 12 weeks.

6. What kind of study products will I receive?

If you agree to participate in the study, the doctor may need to perform some tests and examinations on your child to determine if he/ she is suitable for the study. If he/ she is deemed suitable, he/ she will be provided with REMDII Sensitive® Intensive Moisturising Cream (investigation product). The study products has been registered with the National Pharmaceutical Regulatory Agency (NPRA) from the Malaysian Ministry of Health, certified *halal* and do not contain animal components.

7. What will happen if I decide to take part?

a) Subjects who are eligible to take part in this trial will need to attend to the study site for a total of 4 visits, where qualified medical personnels will attend to the subjects, each taking 45 min to 1 hour, as illustrated in Fig. 1 below.

b) Prior to the study, a screening/baseline study will be conducted (about 1 hour) where the investigators will take note of the subjects conditions for evaluation of study acceptability.

c) Once accepted for the study, subjects will be provided with a moisturizer for a duration of no less than 12 weeks till a year.

d) Subjects will also be provided with non-soap-based shower products for subject's shower purpose throughout the study. Subjects should avoid the usage of soap-based products throughout the study.

e) The correct usage of the cream will be explained by the investigator and the investigator's team. Subjects will be required to apply at least 1 fingertip unit to 2% body surface area.

f) The subjects/parents will need to apply the given moisturizer at least two times a day for 12 weeks (according to the guideline that emphasize the important of using sufficient emollient).

g) Use of permitted topical corticosteroids (mild to mid-potency) as rescue treatment is allowed throughout the study according to the standard rescue treatment. However, subjects need to record the application in the provided diary. As well, any deviation or illness that occurs during the study will need to be recorded in the same diary as well.

h) Explanation of the "Dos and Don'ts" will be conducted to the guardians/parents, and parents will be provided with a dairy and some forms to record the progress and development of the treatment.

i) Initial weight of cream provided will be recorded and weighed. Subjects need to submit the old bottles of cream to investigator where they will be weighed in every visits.. New cream will be provided to subjects, when necessary, in which the weight will be recorded too.

j) Subjects also have to submit their diaries to investigator. New sets of diaries will be provided to subjects.

k) All adverse events that happened will be recorded.

8. When will I receive the trial product and how should it be kept?

You will be given the trial product during the beginning of the study and you will be given enough of the product throughout the treatment period of the study. You must not give the product to anyone else. The trial product has to be brought together to the study site on every visit for weighing and recording (partly used, unused and empty packaging material).

The study staff will instruct you on how the product must be handled and stored. Please ensure that you keep your used and partly used study products after you have finished with them.

9. What are my responsibilities when taking part in this study?

It is most important for your child to be present in all scheduled visits, as specified. All four visits are compulsory. For your child's own security, it is important that you follow your study doctor's instructions throughout the entire duration of the study. It is important that you read and understands all instructions provided carefully before and during the trial. All questions asked by the study staff must be answer honestly and completely. If your condition or circumstances change during the study, you must inform the study doctor immediately. There may be certain medications that you cannot take while participating in this study. The doctor will discuss those medications with you. You must not take any other medications without consulting the study doctor. You must inform your study doctor immediately if you make any changes to any of your current treatments, even those which you have been taking for a long time.

10. What kind of treatment will I receive after my participation in the trial?

The study product and body cleanser will be provided for a period of 1 year from the start of the study trial given that you completed the 12 weeks trial. Whether you complete the study or choose to withdraw early, your doctor will discuss the best alternatives for your future treatment with you.

11. What are the potential risks and side effects of being in this study?

- The clinical trial may require more time and hassle than a non-clinical trial treatment such as fixed visits to the clinical trial site, potential waiting period prior to investigator's assessment and additional fees of the subjects own expense (transportation, food and drinks etc.).
- There may be possible risk of burning and stinging sensation on scratch wounds, irritation, and allergic reaction which is common of topical applications.

Please ask your study doctor if you need more information on risks and side effects. The trial staff will inform you in a timely manner about any new findings or changes about the study product which may affect your health or willingness to continue in this study. Where necessary, you may be asked to reconsent to participate.

12. What are the benefits of being in this study?

- All subjects will be provided with free moisturiser and gentle body cleanser (REMDII® Sensitive, Malaysia) for one year.
- Access to promising new treatments often not available outside the clinical-trial setting.
- Treatment that may be more effective than the standard approach, Vitamin E has been tested to be safe and without known negative side effects.
- Close monitoring, advice, care, and support by a research team of doctors and other health care professionals who understand your disease or condition, free of charge.
- The opportunity to be the first to benefit from a new method under study.
- The chance to play an active role in your own health care and gain a greater understanding of your disease or condition.
- The chance to help society by contributing to medical research. Even if you don't directly benefit from the results of the clinical trial you take part in, the information gathered can help others and adds to scientific knowledge. People who take part in clinical trials are vital to the process of improving medical care.

There may or may not be any benefits to you, however, the information obtained from this study will help improve the treatment or management of other children exhibiting the same symptoms or condition.

13. What if your child is injured during this study?

All subjects will be provided with an insurance protection related to this trial. If your child are injured as a result of being in this study, you should contact your study doctor immediately. The sponsor is not responsible for medical expenses due to pre-existing medical conditions, any underlying diseases, any ongoing treatment process, your and your child's negligence or willful misconduct, the negligence or willful misconduct of your study doctor or the study site or any third parties. You do not lose any of your legal rights to seek compensation by signing this form.

14. What are my alternatives if I do not participate in this study?

You do not have to participate in this study to get treatment for your disease or condition. Alternate treatments which are available are some available steroidal or non-steroidal treatment. The study doctor will discuss in more details the benefits and risks of those treatments with you.

15. Who is funding the research?

This study is sponsored by Lipidware Sdn. Bhd that will pay for all study products and procedures. All other products and procedures that are not required by the study but are part of your routine medical care will have to be paid by you or your insurance. The sponsor will financially compensate the time spent by the study staff, use of facilities, etc., for including you in the study.

16. Can the research or my participation be terminated early?

Yes, you may choose to leave the study at any time. In some cases, the study doctor or the sponsor, due to potential concerns for your safety, may stop the study or your participation as well. If the study is stopped early for any reason you will be informed and arrangements made for your future care. You may be asked to attend a final follow-up visit.

17. Will my medical information be kept private?

All informations obtained in this study will be kept and handled in a confidential manner, in accordance with applicable laws and/or regulations. When publishing or presenting the study results, your identity will not be revealed without your expressed consent. Individuals involved in this study and in your medical care, qualified monitors and auditors, the sponsor or its affiliates and governmental or regulatory authorities may inspect and copy your medical records, where appropriate and necessary.

18. Who should I call if I have questions?

If you have any questions about the study or if you think you have a study related injury and you want information about treatment, please contact the study doctor, Dr. How Kang Nien (Mobile: +6017-6723051) or the study manager, Dr. Nicholas Khong (Mobile: +012-9074568).

Appendix



Figure 1. Study flow chart.

INFORMED CONSENT FORM

Title of Study: **A Phase II open label, single arm, single centre clinical study on the effect of a moisturiser containing tocotrienol rich composition on mild to moderate atopic dermatitis in children**

By signing below I confirm the following:

- I have been given oral and written information for the above study and have read and understood the information given.
- I have had sufficient time to consider participation in the study and have had the opportunity to ask questions and all my questions have been answered satisfactorily.
- I understand that my participation is voluntary and I can at anytime free withdraw from the study without giving a reason and this will in no way affect my future treatment.
- I am not taking part in any other research study at this time.
- I understand the risks and benefits, and I freely give my informed consent to participate under the conditions stated.
- I understand that I must follow the study doctor's (investigator's) instructions related to my participation in the study.
- I understand that study staff, qualified monitors and auditors, the sponsor or its affiliates, and governmental or regulatory authorities, have direct access to my medical record in order to make sure that the study is conducted correctly and the data are recorded correctly. All personal details will be treated as STRICTLY CONFIDENTIAL

- I will receive a copy of this subject information/informed consent form signed and dated to bring home.
- I agree/disagree* for my family doctor to be informed of my participation in this study.

*(*delete which is not applicable)*

Subject:

Signature: I/C number:

Name: Date:

Investigator conducting informed consent:

Signature: I/C number:

Name: Date:

Impartial witness: *(Required if subject is illiterate and contents of patient information sheet is orally communicated to subject)*

Signature: I/C number:

Name: Date: